141 related articles for article (PubMed ID: 30501698)
1. [Relation between single Nucleotide Polymorphisms of CYP3A5 Gene and MDR1 Gene Loci and Risk of CML Cytogenetic Relapse].
Yang ZY; Zhang YS; Liang CX; Zhou ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1644-1648. PubMed ID: 30501698
[TBL] [Abstract][Full Text] [Related]
2. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
3. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
4. [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].
He Y; Zao X; Wei X
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jan; 38(1):34-41. PubMed ID: 33177018
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
6.
Louati N; Turki F; Mnif H; Frikha R
J Oncol Pharm Pract; 2022 Jan; 28(1):39-48. PubMed ID: 33565361
[TBL] [Abstract][Full Text] [Related]
7. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
8. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
Zu B; Li Y; Wang X; He D; Huang Z; Feng W
Pharmacogenomics; 2014 Apr; 15(5):667-77. PubMed ID: 24798723
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
[TBL] [Abstract][Full Text] [Related]
10. Association of C3435T, C1236T and C4125A Polymorphisms of the MDR-1 Gene in Egyptian Children with Acute Lymphoblastic Leukaemia.
Talaat RM; Y K El-Kelliny M; El-Akhras BA; Bakry RM; Riad KF; Guirgis AA
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2535-2543. PubMed ID: 30256048
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia.
Yaya K; Hind D; Meryem Q; Asma Q; Said B; Sellama N
Tumour Biol; 2014 Nov; 35(11):10969-75. PubMed ID: 25087925
[TBL] [Abstract][Full Text] [Related]
12. Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
[TBL] [Abstract][Full Text] [Related]
13. MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy.
Hu W; Huang S; Dong L; Yu C; Li C; Zhang J
Anticancer Drugs; 2019 Mar; 30(3):233-240. PubMed ID: 30779721
[TBL] [Abstract][Full Text] [Related]
14. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
[TBL] [Abstract][Full Text] [Related]
15. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
17. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
Xiong Y; Yuan Z; Yang J; Xia C; Li X; Huang S; Zhang H; Liu M
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):117-24. PubMed ID: 25427746
[TBL] [Abstract][Full Text] [Related]
19. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
20. MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients.
Ni Y; Yin G; Xiao Z; Fan L; Wang L; Wu Y; Wu H; Qian S; Xu W; Li J; Miao K; Qiu H
Tumour Biol; 2016 Jan; 37(1):1237-44. PubMed ID: 26286835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
